Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Seizure Reduction And Cognitive Improvements In Dravet Syndrome
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Seizure Reduction And Cognitive Improvements In Dravet Syndrome
stoke therapeutics发布数据，显示Zorevunersen显著减少癫痫发作并改善Dravet综合征认知能力
- – New data showed improvements in cognition and behavior during the first year of treatment with additional increases demonstrated as treatment continued –
- – Clinical effects observed across the Phase 1/2a and open-label extension studies (OLEs) of zorevunersen are a first in the treatment of Dravet syndrome and support plans for the Company's Phase 3 registrational study –
- – Zorevunersen generally well-tolerated across the studies –
- – Data presented for the first time at the 15th European Epilepsy Congress (EEC) –
- — 新数据显示，在治疗的第一年中，认知和行为有所改善，随着治疗的继续，认知和行为也有所改善 —
- — 在zorevunersen的1/2a期和开放标签扩展研究（OLE）中观察到的临床效果是Dravet综合征治疗的首例，也是该公司3期注册研究的支持计划—
- — Zorevunersen 在整个研究中普遍耐受性良好 —
- — 在第十五届欧洲癫痫大会（EEC）上首次公布的数据 —